Women's Health Deal Benchmarks
Endometriosis, uterine fibroids, menopause, and fertility deal benchmarks. Benchmarks derived from 58 verified transactions.
58
Total Deals
$210M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
28
license
18
acquisition
8
collaboration
1
option
1
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
Sage Therapeutics → Supernus Pharmaceuticals Zurzuvae (zuranolone) acquisition | acquisition | $561M | $795M | Jun 2025 |
Evopoint Biosciences → Astellas Pharma XNW27011 | license | $130M | — | May 2025 |
Kissei Pharmaceutical → Theramex Linzagolix (YSELTY) | license | $50M | $200M | Dec 2024 |
Organon → Samsung Bioepis endometriosis | license | $200M | $800M | Oct 2024 |
Dermavant/Roivant → Organon Vtama (tapinarof) acquisition | acquisition | $175M | $1.2B | Sep 2024 |
Insilico Medicine → Menarini/Stemline MEN2312 (KAT6A inhibitor) | license | $12M | $500M | Jan 2024 |
Evofem Biosciences → Aditxt Phexxi | acquisition | $25M | $25M | Nov 2023 |
ObsEva → XOMA/Kissei endometriosis | license | $55M | $350M | Jul 2023 |
Sage Therapeutics → Biogen postpartumDepression | collaboration | $875M | $1.5B | Jul 2023 |
Dare Bioscience → Bayer vulvodynia | license | $20M | $300M | Jul 2023 |
Benchmark Your Women's Health Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 58 verified women's health transactions.
Run Women's Health Benchmark